Imatinib (STI571, Gleevec/Glivec) is a potent selective tyrosine kinase inhibitor and is used successfully in the treatment of chronic myeloid leukemia (CML). While karyotype alterations, in addition to the Philadelphia chromosome, are a common phenomenon of progressing CML, the observation of BCR-ABL-negative leukemic clones with distinct aberrant karyotypes under an imatinib regimen is not yet understood. Here we test the hypothesis that such tumor clones may be induced de novo from normal cells by imatinib. In vitro experiments with varying drug concentrations (5-20 lM) were performed on normal human dermal fibroblasts (NHDF), Chinese hamster embryonal and Indian muntjak fibroblasts. After 3 weeks of treatment, analysis of cell cultures by centrosome immunostaining and conventional cytogenetics revealed that imatinib induced centrosome and chromosome aberrations in all cultures in a significant dose-dependent and species-independent manner. Moreover, the results of NHDF long-term culture experiments demonstrated that aberrant phenotypes, emerging under imatinib treatment for 12 weeks, were not reversible after prolonged propagation omitting the drug. These observations suggest a causative role of imatinib in the origin of centrosome and karyotype aberrations (genetic instability) and thus may explain the emergence of clonal chromosomal abnormalities in BCR-ABL-negative progenitor cells under imatinib therapy.
Introduction
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder with the presence of the Philadelphia (Ph) chromosome and the bcr-abl fusion gene. The novel chimeric gene is expressed as BCR-ABL fusion protein with constitutively enhanced tyrosine kinase activity and has been shown to be the key factor in both induction and progression of CML. 1 As the tyrosine kinase activity of the BCR-ABL protein is essential for transformation, it is an ideal therapeutic target. 2 Imatinib is a highly effective inhibitor of c-ABL, v-ABL, and BCR-ABL protein kinases and has revolutionized drug therapy of CML. Clinical responses in chronic-phase CML are unprecedented, with rates of complete cytogenetic response of more than 40% in patients after failure of interferon-alpha and more than 80% in newly diagnosed patients. 2 Although designed for treatment of ABL-associated human leukemias, imatinib occupies the ATP-binding sites of several other tyrosine kinases such as the stem cell factor receptor c-KIT, the platelet-derived growth factor receptors (PDGFR) alpha and beta, 3 and the abl-related gene product ARG. 4 Recently, the SRC family tyrosine kinases LCK, FRK, FYN, and the macrophage colonystimulating factor receptor c-FMS have been identified as targets of imatinib. 5, 6 Furthermore, inhibitory effects on the serine/ threonine-protein kinase c-RAF-1 have been described, suggesting effects on substrate phosphorylation by serine/threonine kinases as well. 2 While cytogenetic changes in addition to the Ph chromosome are a common phenomenon of progressing CML and have been explained by genetic instability caused by the unrestrained tyrosine kinase activity of BCR-ABL, 7 the appearance of Ph-negative clones with aberrant karyotypes that are able to expand in a BCR-ABL-independent manner is considered to be induced by prodromal therapy with cytostatic agents that act as genotoxic drugs. These Ph-negative clones with distinct cytogenetic markers, persisting in parallel to the Ph-positive clones in blood and bone marrow, are detectable after treatment with conventional cytostatic or immunomodulatory agents such as hydroxyurea, busulfan, and interferon-alpha. 8, 9 Having received such therapy, patients display a higher risk for developing secondary malignancies. [10] [11] [12] [13] Clonal evolution of aberrant Ph progenitors have been associated with late onset of acute myeloid leukemia (AML) 9 and myelodysplastic syndromes (MDS). 10 After imatinib therapy, the emergence of Ph-negative clones distinctly different in their karyotypes from the Ph-positive clone is reported with variable frequency. [10] [11] [12] [14] [15] [16] Preliminary data suggest that 3% up to 17% of patients treated with imatinib display such clonal evolution. 14, 17 Common changes are trisomy 8 and monosomy 7. 10, 12, 14 Since most patients receive conventional cytostatic therapy before imatinib treatment and results from long-term follow-up studies under first-line imatinib therapy are not available yet, the role of imatinib in the origin of Ph-negative clones is still unclear.
Recently, we have demonstrated that centrosome defects are an early event in the transformation process of CML and occur prior to chromosome instability at the earliest identifiable step in CML development. 18, 19 Since CML is considered to be caused by a single genetic event, some authors argue that early centrosome aberrations are the consequence of BCR-ABL expression, leading to karyotype alterations, aneuploidy, and genetic instability. 19 The occurrence of similar karyotypic alterations in BCR-ABL-negative progenitor cells under imatinib raises the question whether centrosome-associated mechanisms possibly involving ABL or other imatinib-sensitive kinases may be responsible.
Since most studies on imatinib's antiproliferative effects have been performed on myeloid tumor cell lines containing BCR-ABL, 20 little is known about the effects of imatinib on nonmalignant (Ph-negative) primary cells. Therefore, we decided to examine the centrosome status and karyotypes of normal primary cells treated with imatinib. We report here the results of imatinib treatment of short-and long-term cultures of normal human dermal fibroblasts (NHDF), Chinese hamster embryonal fibroblasts (CHE) and Indian muntjak fibroblasts (IMF) addressing the following questions:
(i) Does treatment of normal cells with imatinib cause chromosomal aberrations and when, how do they correlate with the centrosomal status? (ii) Does drug removal reverse the aberrant phenotypes?
Cell cultures and methods

Primary cells
NHDF, (Promocell GmbH, Heidelberg Germany), CHE, derived from embryos of an inbred line of animals described previously, 21 and IMF, (American Type Culture Collection, Manassas, VA, USA) were grown in RPMI 1640 medium with 10% fetal calf serum, 1% calf serum, antibiotics, and antimycotics (Invitrogen Inc., Groningen, The Netherlands) and treated with 5, 10, or 20 mM of imatinib (provided by Novartis, Basel, Switzerland).
Centrosome staining and digital immunofluorescence
Cell fixation and centrosome immunostaining were performed as described previously. 18 
Cytogenetics
Generally, chromosome analyses were performed on cells from subconfluent cultures as described. 18 Chromosomes of CHE and IMF were analyzed based on banding patterns that have been described previously. 22, 23 Two clonal aberrations (additional chromosomal material on the long arm of chromosome 4, add(4)(q), and an additional marker chromosome, þ mar) were observed in both untreated and treated CHE cells. These clonal aberrations were not drug induced and therefore were disregarded.
Evaluation and calculation of centrosome aberrations were performed as described previously. 18 
Statistical analysis
The general linear model algorithm was used to compare species, control, and drug treatment groups. Statistical analyses were carried out with the SAS software package, release 8.02 (SAS Institute Heidelberg, Germany).
Results
Short-term cultures of NHDF, CHE, and IMF cells
To investigate whether treatment with imatinib may cause centrosome and chromosome alterations, parallel cultures of NHDF, CHE, and IMF cells were propagated for 3 weeks each in medium containing imatinib at final concentrations of 0, 5, 10, or 20 mM. After 3 weeks, centrosomes were analyzed using indirect immunostaining of pericentrin and the chromosomal status was examined. All imatinib-treated cell lines displayed numerical and structural centrosome and chromosome aberrations as compared to control cells grown without imatinib (Table 1; Supplementary Table 1) . Occurrence of alterations was species-independent and increased in a strictly dose-dependent manner (Figure 1a -c). (Figure 1a) .
As shown in Table 1 and Figure 1 (b and c) similar results were obtained in CHE and IMF cells. However, the highest percentage of numerical chromosomal aberrations was found in IMF cultures. This points to a selective pressure against structurally altered, phenotypes probably due to the small number of chromosomes (7,XY 1 Y 2 ). Qualitative differences in aberrant centrosome phenotypes were observed when IMF cells were compared to both human and hamster cells. As shown in 
NHDF long-term cultures
To investigate the impact of imatinib on human cells in longterm cultures and to find out whether the induced aberrations are reversible after removal of the drug, parallel NHDF cultures were treated with 5, 10, or 20 mM imatinib for 12 weeks. At this time point, all cultures were split. Three cultures (experimental arm 1) received further treatment with their previous imatinib concentration, while the three remaining cultures (experimental arm 2) were grown without imatinib, similar to the negative control cultures. Centrosome and chromosome analyses were performed after 4 and 8 weeks of further propagation adding up to 16 and 20 weeks of total culture, respectively (Figure 1d and e; Table 2; Supplementary Table 2) . Similar dose-dependent increases in centrosome and chromosome aberrations were found in long-term imatinib-treated NHDF cells in comparison to the preceding short-term experiments (Po0.0001). Omitting drug treatment after 12 weeks revealed a clear decrease in the percentage of centrosome and chromosome aberrations as analyzed after 16 and 20 weeks of total culture time (Po0.0001) (Figure 1d and e) . However, normalization of phenotypes was not reached after prolonged culture for 4 and 8 weeks, suggesting irreversibility of imatinib-induced aberrations and imatinib-independent autocatalytic mechanisms perpetuating genetic instability.
Discussion
The appearance of chromosomal abnormalities in Ph-negative cells under imatinib is becoming a major concern in the treatment of CML. So far, uncharacterized side effects of imatinib therapy seem to result in functional disturbance of normal hematopoiesis or even in secondary karyotypic abnormalities as observed in Ph-negative progenitor cells of patients with major cytogenetic response. 2, 10, 24 A discussion considering several hypotheses is still ongoing. 2 
Figure 1
Correlation between chromosome and centrosome aberrations in NHDF (a), CHE (b), and IMF (c) cultures after short-term treatment (21 days) in medium containing 5, 10, or 20 mM imatinib (Ima). For NHDF long-term cultures, centrosome and chromosome status were analyzed after 16 (16w þ Ima) (d) and 20 weeks (20w þ Ima) (e) of total drug treatment and after four (4w -Ima) and 8 weeks (8w -Ima) of prolonged propagation omitting the drug after 12 weeks (12w þ Ima) of imatinib pretreatment (d, e). P-values o0.0001 apply for all experiments.
Imatinib and genetic instability A Fabarius et al (i) Ph-negative aberrant clones may represent a preleukemic stage and the acquisition of the Ph chromosome may be a secondary event. Imatinib treatment will then favor proliferation of these pre-existing clones. 25, 26 (ii) The Ph translocation and other cytogenetic abnormalities are induced independently in different progenitor cells. The latter could be due to prodromal CML therapy by administration of cytostatic agents that act as genotoxic drugs. 8, 10, 12, 25 (iii) Imatinib itself induces de novo chromosomal aberrations in Ph-negative hematopoietic progenitor cells (compare data sheet Novartis, Switzerland). ABL tyrosine kinase interacts with several proteins such as p73, 27 DNA-PK, 28 Atm, 29 and Rad51 30 involved in DNA repair mechanisms. Thus, inhibition of ABL activity may negatively affect DNA repair fidelity and promote secondary chromosomal changes.
Without rejecting the second hypothesis, our in vitro experiments clearly support the de novo hypothesis by demonstrating that imatinib is able to induce chromosome and centrosome alterations in human and mammalian normal cells in a dose-dependent manner. Allowing for the common phenomenon of spontaneously occurring karyotypic alterations in long-term cultures, 31 the increase of aberrant cells in imatinib-treated cultures compared to untreated controls is highly significant, dose-dependent, and species-independent, pointing to a common pathomechanism in human and mammalian cells. Once genetic alterations have manifested, aberrant clones may persist in an imatinib-independent manner. 31 Our findings of up to 58% aberrant human cells in short-term cultures after treatment with therapeutic doses of imatinib suggest that cells in vitro are either more vulnerable to the drug or lack the selective pressure leading to effective elimination or suppression of BCR-ABL-negative aberrant clonal phenotypes in vivo. Immunosurveillance may play an important role in the elimination of aberrant clones in CML patients. Recently, suppression of T-cell proliferation has been reported as an unexpected side effect of imatinib and the drug has been suggested as a clinically useful immunosuppressant. 32, 33 Impaired T-cell-mediated immunosurveillance could explain the increasing number of reports dealing with the incidence of secondary hematologic malignancies and infections in patients under imatinib. 14, 15, 32, 34 The mechanisms by which imatinib affects genetic stability in normal cells are unknown, as no uniform influence of the drug on gene expression patterns in PhÀ CD34 þ cells has been detectable in vivo. 24 However, they are likely due to its function as a potent kinase inhibitor by stereochemically mimicking ATP. The number of ATP-binding protein kinases encoded by the human genome has been estimated between 500 and 1000 and about one-third of all mammalian proteins undergo phosphorylation. 35 Assuming 100 000 gene products in total, then an 'average' protein kinase phosphorylates up to 30 proteins irrespective of the fact that many proteins are phosphorylated by two or more protein kinases. 36 The observed effects of imatinib on chromosomal stability may be due to the 'specific' inhibition of one or more of its known main targets c-ABL, c-KIT, PDGFR, ARG, or c-FMS. For example, c-ABL is an essential regulator of the RAD51 protein that plays a pivotal role in homologous recombination and is involved in DNA doublestrand break repair and genome maintenance. 37 In normal cells, c-ABL phosphorylates RAD51 and thereby inhibits DNA binding and function of RAD51 in ATP-driven DNA strand exchange reactions. 30 Inhibition of c-ABL with imatinib may therefore, reduce the rate of phosphorylated RAD51, enhancing homologous recombination events possibly accounting for the observed chromosomal instability (structural aberrations). This theory is supported by cell culture experiments showing that expression of a RAD51 dominant-negative mutant protein in several cell lines led to spontaneous centrosome fragmentation and increased aneuploidy.
38 RAD51-deficient cells arrest in G2 phase and form supernumerary functional centrosomes leading to genomic destabilization. 39 Moreover, c-ABL binds directly to p53 and is involved in p53-dependent G1 arrest response. Defects in G1 arrest and DNA repair by c-ABL inhibition may predispose cells to replication of damaged DNA leading to genetic instability. c-ABL is also an upstream effector of the proapoptotic JNK/SAPK and p38 MAPK pathways and c-ABLdependent inhibition of PI 3-kinase also contributes to induction of apoptosis. 40 Since c-ABL plays key roles in cellular growth arrest, DNA repair, and apoptosis, the drug-mediated inhibition of c-ABL could explain the observed genetic instability.
Since the incidences of centrosome and chromosome alterations were strictly correlated in all experiments, it is conceivable that the direct involvement of centrosomes or centrosome-associated imatinib-sensitive kinases cause karyotype destabilization. This is in concordance with our recent study demonstrating the early presence of centrosomal abnormalities during the course of malignant progression in CML -significantly before the advent of chromosomal aberrations. 18 Since numerical Figure 2 Centrosome status of NHDF, CHE, and IMF short-term cultures. Indirect immunofluorescence staining of centrosomes was performed on normal untreated (1-4) and on imatinib-treated cells (5) (6) (7) (8) . Cells were immunostained with an antibody to pericentrin, followed by a Cy3-conjugated secondary antibody.
aberrations prevail in all aberrant karyotypes (Tables 1 and 2) , centrosome defects may mechanistically contribute to the observed chromosomal instability. Besides the already mentioned imatinib-induced RAD51 deficiency leading to supernumerary centrosomes, LCK and FYN, which have been recently identified as targets of imatinib, may be important for centrosome maintenance. 5 The association of LCK in human T cells with pericentrosomal vesicles and of FYN in Jurkat T cells and T lymphoblasts with the centrosome and mitotic spindle suggests that these kinases may be important for mitosis and cell cycle regulation. 41 Therefore, inhibition of these kinases may affect centrosomal fidelity resulting in the observed effects.
Inhibitory effects of imatinib on any other so far unknown target or a combination of targets discussed before may be responsible for our findings. Since ATP-binding clefts are stereochemically conserved, an ATP-mimicking molecule cannot be exclusively specific for one single kinase target. Although not experimentally confirmed except for Raf-1, 2 imatinib may also affect other kinases, including serine/threonine kinases, albeit at levels that may not be detectable by current methods. Since nearly all aspects of the cell cycle are controlled by reversible phosphorylation of proteins, even minor changes in kinase activities may affect cellular signal transduction cascades and influence fidelity of cell cycle regulation. Several families of serine/threonine kinases such as Polo-like and Aurora family kinases play key roles in cell cycle regulation and centrosome duplication. 42, 43 In conclusion, our results strongly support the hypothesis that imatinib can cause the emergence of clonal chromosomal abnormalities. Due to the lack of normal cell testing, it is still unclear whether imatinib treatment will induce genetic instability also in patients with gastrointestinal stromal tumors (GIST) or other tumors.
Our observations indicate the need for long-term follow-up studies on patients to see how the natural history of CML will be modified by the drug. Moreover, novel ATP-mimicking inhibitors of BCR-ABL (BMS354825, AMN107) should be thoroughly tested for their potential side effects on centrosome and chromosome status. conc, concentration; aberr, aberration; num, numerical; struc, structural; centros, centrosomes; chromos, chromosomes.
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